SEK 27 million from the Swedish Cancer Society awarded to Sandra Lindstedt’s team in Lund for early detection of lung cancer
PExA congratulates Professor Sandra Lindstedt and her research group at Lund University on receiving SEK 27 million in research funding from the Swedish Cancer Society, as part of the organisation’s largest-ever initiative focused on the early detection of cancer.
The project aims to develop a simple and non-invasive test for the early diagnosis of lung cancer by analysing exhaled particles. The method is based on PExA’s non-invasive technology, which enables the collection of biological material from the small airways of the lung – without requiring any invasive procedures.
Lung cancer is the leading cause of cancer-related deaths worldwide, largely because it is often discovered too late for effective treatment. Early detection fundamentally changes treatment opportunities, and the research group in Lund has already identified promising results showing that specific protein patterns in PEx samples can distinguish between healthy individuals and patients with lung cancer.
In the Swedish Cancer Society’s press materials, Professor Lindstedt describes the aim of further developing the method into a fast and accessible test that can also be used in primary care:
- We have shown that our method can distinguish between healthy individuals and people with lung cancer, and even identify the tumour’s genetic profile. We now want to develop a rapid test that can be used in primary care, so that more people receive a diagnosis in time and can be treated earlier, says Professor Sandra Lindstedt, Lund University.
This area of research aligns with PExA’s long-term ambition for its technology to enable non-invasive sampling from the small airways for future diagnostic applications.
- We are very pleased to see Sandra’s success and proud that the PExA technology is being used in this research. This represents an important step towards the diagnostics of the future, where early and non-invasive sampling can help save lives, says Tomas Gustafsson, CEO of PExA AB.
PExA and Professor Lindstedt have recently submitted a joint patent application related to lung cancer biomarkers, based on PEx sample data from a lung cancer study conducted in Lund.
Read more in the Swedish Cancer Society’s press release (in Swedish):
https://via.tt.se/pressmeddelande/4132389
Click here to read this news as PDF
Professor Sandra Lindstedt and PhD student Gabriel Hirdman in front of the PExA instrumentet, picture from Sydsvenska Dagbladet.
For further information, please contact:
Tomas Gustafsson, CEO, info@pexa.se
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.